Quantbot Technologies LP Lowers Holdings in DENTSPLY SIRONA Inc. $XRAY

Quantbot Technologies LP trimmed its position in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 62.6% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 68,202 shares of the medical instruments supplier’s stock after selling 114,223 shares during the quarter. Quantbot Technologies LP’s holdings in DENTSPLY SIRONA were worth $865,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. Parkside Financial Bank & Trust grew its holdings in shares of DENTSPLY SIRONA by 620.6% during the second quarter. Parkside Financial Bank & Trust now owns 1,715 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 1,477 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in DENTSPLY SIRONA during the first quarter valued at approximately $26,000. True Wealth Design LLC boosted its holdings in DENTSPLY SIRONA by 273.0% in the second quarter. True Wealth Design LLC now owns 2,376 shares of the medical instruments supplier’s stock worth $38,000 after purchasing an additional 1,739 shares during the last quarter. Central Pacific Bank Trust Division boosted its holdings in DENTSPLY SIRONA by 100.0% in the third quarter. Central Pacific Bank Trust Division now owns 4,000 shares of the medical instruments supplier’s stock worth $51,000 after purchasing an additional 2,000 shares during the last quarter. Finally, Versant Capital Management Inc grew its position in DENTSPLY SIRONA by 878.6% in the 3rd quarter. Versant Capital Management Inc now owns 4,883 shares of the medical instruments supplier’s stock worth $62,000 after purchasing an additional 4,384 shares during the period. 95.70% of the stock is owned by hedge funds and other institutional investors.

DENTSPLY SIRONA Stock Performance

NASDAQ XRAY opened at $12.74 on Friday. The firm has a market cap of $2.54 billion, a price-to-earnings ratio of -4.25, a price-to-earnings-growth ratio of 1.56 and a beta of 0.97. The company has a quick ratio of 1.03, a current ratio of 1.51 and a debt-to-equity ratio of 1.50. The business has a 50-day moving average price of $12.63 and a 200-day moving average price of $12.48. DENTSPLY SIRONA Inc. has a twelve month low of $9.85 and a twelve month high of $17.18.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a negative net margin of 16.25% and a positive return on equity of 18.85%. The business had revenue of $961.00 million for the quarter, compared to the consensus estimate of $926.40 million. During the same period last year, the business posted $0.26 EPS. The firm’s revenue for the quarter was up 6.2% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, equities research analysts predict that DENTSPLY SIRONA Inc. will post 1.84 EPS for the current fiscal year.

DENTSPLY SIRONA Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 9th. Stockholders of record on Friday, December 26th were given a dividend of $0.16 per share. The ex-dividend date was Friday, December 26th. This represents a $0.64 annualized dividend and a dividend yield of 5.0%. DENTSPLY SIRONA’s dividend payout ratio (DPR) is presently -21.33%.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Bank of America upgraded shares of DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $13.00 to $17.00 in a research note on Thursday, February 19th. Wells Fargo & Company upped their target price on shares of DENTSPLY SIRONA from $12.00 to $13.00 and gave the company an “equal weight” rating in a report on Friday, February 27th. Zacks Research upgraded shares of DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a research report on Monday, March 2nd. UBS Group dropped their price target on shares of DENTSPLY SIRONA from $17.00 to $16.00 and set a “buy” rating on the stock in a research note on Tuesday, February 3rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of DENTSPLY SIRONA in a research report on Wednesday, January 21st. Three analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $14.42.

Insider Activity at DENTSPLY SIRONA

In other news, Director Gregory T. Lucier sold 82,200 shares of the business’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $11.14, for a total value of $915,708.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 0.50% of the company’s stock.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.